Tim has worked in the life sciences industry for 30 years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips.
Between 2007 and 2015 he served on 10 boards, 5 as chair, where he successfully executed 2 trade sales and raised significant equity financing, including an IPO. Tim’s current governance portfolio covers life sciences and healthcare and education, both public and private. This includes:
- board roles as Non-Executive Director at NICE
- various European MedTech Supervisory Board roles
- Professor of Practice at King’s College London’s School of Management and Business.
In his role as Vice Chair, Tim oversees the technology appraisals and highly specialised technologies appeals process.
Professor Sheena Asthana
Professor Sheena Asthana is Professor of Health Policy at the University of Plymouth. Her research and teaching focus is on inequalities in health and health care, international public health and evidence-based public health.
She has worked with NICE to produce systematic reviews, evidence synthesis and economic analyses to inform our public health programme. Sheena brings experience of a wide variety of board appointments.
Rima is Chair of our audit and risk committee and is our senior independent director.
Professor Angela Coulter is a health policy analyst and researcher, with special interests in patient and public involvement. Her previous roles include Chief Executive of Picker Institute Europe, Director of Policy and Development at the King’s Fund, Director of the Health Services Research Unit at the University of Oxford and Director of Global Initiatives at the Informed Medical Decisions Foundation.
Angela has published more than 300 research papers and reports. She is the author of several books including The European Patient of the Future, winner of the 2004 Baxter Award. Her work has received awards from the Donabedian Foundation of Barcelona in 2012 and the International Shared Decision Making Conference in 2013.
Professor Martin Cowie
Professor Martin Cowie is Professor of Cardiology at Imperial College and an Honorary Consultant Cardiologist at the Royal Brompton and Harefield NHS Foundation Trust.
Since 2003 he has been a clinical advisor for NICE on our acute and chronic heart failure guidelines, quality standards, commissioning guides, patient decision aids, and technology appraisals. In 2012 he became a NICE
His major clinical and research interests are in health technology assessment and the delivery of efficient and effective care for patients with heart failure, focusing on new technologies: diagnostics, drugs or devices
Elaine Inglesby-Burke has been a registered nurse since 1980. Her previous roles include being a nurse specialist manager at St Helens and Knowsley Hospital Trust and Director of Nursing at The Walton Centre in Liverpool. Most recently, Elaine was appointed Deputy Chief Executive at Salford Royal NHS Foundation Trust. She is also on the governing body at St Helens Clinical Commissioning Group and Willowbrook Hospice in St Helens.
Elaine has also played a significant role in national health campaigns, having been a member of the Prime Minister’s Nursing and Care Quality Forum. She was also involved with the Berwick National Advisory Group on the Safety of Patients in England, which is a group of healthcare experts that was set up to examine patient safety issues in the NHS.
Last year, Elaine was awarded a CBE on the Queen’s Birthday Honours List for her services to nursing.
Dr Rima Makarem
Dr Rima Makarem has been Audit Chair in several NHS organisations, recently at NHS London and now at University College London Hospital. She is also the Chair for the National Travel Health Network and Centre (NaTHNaC), an Independent Council Member at St George’s University of London and a Board Trustee at Anchor Trust, a leading national provider of care homes and sheltered accommodation.
Rima has previously worked in the pharmaceutical industry in a number of roles including Director of Competitive Excellence at GlaxoSmithKline.
Tom Wright CBE is Chief Executive of Guide Dogs. He was previously CEO of Age UK and chair of the Richmond Group of 14 leading health charities. Tom has extensive experience in the health and social care sector.
Uday Bose is currently Corporate Vice President, Head of Global Marketing, for Boehringer Ingelheim, Oncology. Based in Germany, he is responsible for all commercial aspects
Uday has extensive experience in the industry gained over 20 years. He started in health economics and has worked on NICE submissions and negotiations from his previous industry roles. The vast majority of his experience is with
Stuart is a senior health economist and market access expert specialising in pharmaceuticals, health technology appraisal (HTA) and health policy. He holds a BA (Hons) in politics and economics (1st Class) from the University of Northumbria at Newcastle, an MSc in health economics (distinction) from the University of York, and an MBA (distinction) from the Imperial Business School. Stuart is currently the head of value & access and public affairs for Sanofi Pasteur in the UK and Ireland. He was previously head of market access for UK & Ireland Biogen Idec (a biotechnology company specialising in multiple sclerosis).
Prior to this, he was head of health economics & epidemiology in the UK for Sanofi Pasteur MSD and worked as a health economics consultant and policy adviser specialising in HTA, pricing and reimbursement and local market access pathways in the NHS.
Stuart has over 12 years of experience leading and managing multiple HTAs including for NICE, the Scottish Medicines Consortium (SMC), the All Wales Medicines Strategy Group and the National Centre for Pharmacoeconomics. As part of these HTA submissions, Stuart has been responsible for overseeing patient access schemes and the implementation of pricing agreements. He has also led and managed HTA and pricing submissions in Australia, New Zealand, Canada, Germany, France, Italy, Spain, Portugal, Sweden, Denmark, Norway, Finland and Eastern Europe. He has experience in leading national tenders for UK-wide vaccination programmes and liaising with the Joint Committee on Vaccination and Immunisation (JCVI).
Stuart is a fellow of the Royal Society of Public Health, a member of the New Drugs Committee for the SMC, and also an elected local councillor in the Royal Borough of Windsor & Maidenhead where he serves as the lead member for adult social care and public health.
Dr Mark Chakravarty
Mark holds a degree in Pharmacology and qualified in Medicine at the University of Manchester, UK, in 1995. He then held various hospital appointments in clinical medicine before taking a joint Medical Adviser post with the NHS Executive in the North West.
During this time Mark was the Chairman of the Northwest Junior Doctors Committee,
Mark held various roles of increasing seniority in Procter & Gamble from 1999 to 2017, including Head of Global Communications for Baby, Feminine & Family Care. Mark joined Novartis in 2017 as the Global Head of Communications and Patient Advocacy for Pharma.
Dr David Gillen
Dr David Gillen (BSc MD FFPM) has been a member of the Appeal Committee since 2012. He is Medical Director for Celgene UK and Ireland. Prior to this
David qualified in Medicine from St Mary's Hospital in 1992. During his undergraduate medical
Beyond clinical research, David has served on the Innovation
Patrick is Executive Director, World Wide Health Economics and Outcomes Research (WWHEOR) Markets at Bristol-Myers Squibb (BMS). He leads the team responsible for supporting country health technology assessment (HTA) submissions and access, for all countries outside of the US. He also leads WWHEOR HTA policy initiatives and is a member of the European Federation of Pharmaceutical Industries and Associations HTA Task force.
Before this role, Patrick led the BMS UK & Ireland Market Access function responsible for the HTA submissions to NICE, Scottish Medicines Consortium, All Wales Medicines Strategy Group and National Centre for Pharmacoeconomics. He also led the BMS HTA policy strategy with the Association of the British Pharmaceutical Industry. Previously Patrick worked at GSK for 14 years in Sales & Marketing, HEOR and Market Access.
Prior to GSK, Patrick worked as an oncology pharmacist for 8 years. He holds a Diploma in Clinical Pharmacy, a Masters in Health Economics and an MBA from Henley Management School.
Dr Mercia Page
Dr Page qualified in medicine from Kings College Hospital Medical School and spent 8 years in hospital practice in the NHS, before joining the pharmaceutical industry. She gained experience in clinical research and specialised in pharmaceutical medicine. She also completed an MBA from Ashridge in 2001.
Dr Page joined NICE in autumn 2003 as the Associate Director for the Guidelines Programme, and became the Director of the Centre for Clinical Practice. Mercia was a Director of Medical Affairs at MSD Ltd between April 2008 and March 2016. She was appointed to SMC as an industry member between 2009 and 2012. She is now a consultant pharmaceutical physician.
David is the Associate Director for Health Economics and Outcomes Research (HEOR) at Bristol-Myers Squbb (BMS) UK & Ireland. David leads the BMS HEOR team and oversees all health economic activities. He's accountable for ensuring scientifically robust evidence submission dossiers are prepared for all UK and Irish Health Technology Appraisal bodies.
David has been active in health technology appraisals for over 10 years. He previously held positions with other Association of the British Pharmaceutical Industry (ABPI) member companies: Lundbeck, Novartis, and AstraZeneca.
David currently represents BMS at ABPI for health technology assessment related work streams. He was previously a member of the NICE topic selection panel for mental health and a health economist industry representative on the New Medicines Group for the All Wales Medicines Strategy Group.
David holds a PhD in neurobiology from the University of Edinburgh and a postgraduate diploma in health economics from the University of York.
Tony has a background at UK and European Board level in business development and marketing. He has a long association helping fund research into neuroblastoma a rare and aggressive form of cancer predominantly affecting children under 5. He joined Neuroblastoma UK as fundraising trustee prior to being elected their chair in February 2018.
He has been a patient and parent expert representative on the NICE single technology appraisal for dinutiximab beta as well as being a patient and carer expert within the Scottish Medicines Consortium. He was involved in the design, build and operating consortia for the private finance initiatives at St Helens and Knowsley, Sherwood Forest and Peterborough Hospitals. He is involved with the All Party Parliament Group for cancer within children and young adults and works closely with the Children’s Cancer and Leukaemia Group within their special interest group for neuroblastoma. He volunteers for the MurrayParish Trust helping to raise funds to build a new paediatric Intensive care unit at Southampton Hospital. He is a recipient of a CREST award for work in training and development of young people.
Aside from this, Tony is a Registrar of Ceremonies and conducts marriages throughout the year and is an invigilator for schools in Hampshire.
John Morris has been a member of the Appeal Committee since 2011. Dr Morris's career began in pharmaceutical and crop protection scientific research. During this time he also developed an interest and expertise in psychodynamic counselling and interpersonal skills training. He then took these varied experiences and skills to the voluntary sector, managing information, support and advocacy services in two health charities, covering haemophilia and thrombosis and associated conditions such as hepatitis C and HIV.
Membership of another charity's advisory panel, the Long-term Medical Conditions Alliance and Patients in NICE gave him a broader understanding of the needs of people living with medical conditions. Having twice been a patient expert on hepatitis C NICE technology appraisals, he then joined the Royal College of Physicians to project manage the development of NICE clinical guidelines, primarily working on the COPD update. Most recently, he applied his ability of ‘translating' complex medical information into
He is passionate about empowering people to be self-managers of their health conditions and to participate fully in
Professor Alan Silman
Lay representative and appeal panel chair
Alan is an epidemiologist and rheumatologist. He is currently Professor of Musculoskeletal Health at Oxford University with specific interests in device epidemiology and in multimorbidity
From 2007 to 2014 Alan was Medical Director of Arthritis Research UK. In that post, he was responsible for providing the strategic direction and leadership to the charity’s research and education activities. Prior to joining Arthritis Research UK, he was director of ARUK’s Epidemiology Unit in Manchester for 18 years. Until the end of 2011, Alan was a consultant rheumatologist at the Manchester Royal Infirmary.
Some of his milestones include being elected as a Fellow of the Academy of Medical Sciences and awarded Honorary Doctorates from
His external responsibilities have included membership of the MHRA Pharmacovigilance Expert Advisory Group;
Colin Standfield has been a member of the Appeal Committee since 2011. Colin is an Oxford MA in English and has a background at Board level in advertising and marketing. He also has a long association with substance misuse issues and worked for 10 years as a Trustee and then Development Officer with Battling Addictions Together, a user-led Ealing charity helping people recover from drug and alcohol problems. He is a Trustee of Drugscope and has been involved with a number of Ealing and pan-London committees in the field, including the Ealing Drug and Alcohol Task Group and the Greater London Alcohol and Drug Alliance. He is Church Council Secretary and a former Senior Steward at Hanwell Methodist Church.
He is a skilled presenter and has experience of service improvement within the NHS; he has run redesign programmes for Substance Misuse and Mental Health teams in boroughs across the country. Colin was the elected Chair of the Ealing and West London Research Ethics Committee for over four years and was a Non-Executive Director of Ealing Primary Care Trust from 2004 to 2007.
Lay representative and appeal panel chair
Paddy Storrie is a history graduate and has been involved as a lay member with NICE since 2004. His initial four years were as a member of the Citizens' Council, and between 2009 to 2014 as a lay member on Technology Appraisals Committee
Paddy has experience as a member of the MHRA Patient and Public Engagement Expert Advisory Group. He is on the Steering Committee of the
Outside education and health, he has been involved in long-term projects with Stonewall and The Soldiers' Charity.
Since 2013 Alan has spent an increasing amount of time as a patient/public representative in a variety of local, regional and national roles. His current positions include being Lead Governor of Gloucestershire Hospitals NHS Foundation Trust, a member of the Steering Group for Bristol Biomedical Research Centre, Chair of Gloucestershire Healthwatch and a Patient Public Voice member of NHS England’s On-Line in Primary Care Stakeholder Forum.
After 15 years in civilian education, including 2 years as a Head Teacher, Alan was a late entrant to the Royal Air Force. He spent 23 years as a Royal Air Force Training Officer. In his final six years he was the Royal Air Force’s focal point for training and education policy. After this, he spent 3 years as the training specialist for an aviation company.
Kevin O’Shaughnessy has been a Consultant Clinical Pharmacologist since 1995. He studied Pharmacology before completing his medical training in Oxford with post-graduate training at the Hammersmith Hospital London.
He is currently an honorary Consultant Physician at Addenbrookes Hospital, Cambridge and a Reader in Clinical Pharmacology at the University of Cambridge. He also undertakes basic research into hypertension and has an active role in clinical pharmacology training for the East of England.
Mr Christopher Rao
Mr Christopher Rao is a Specialist Registrar in General Surgery in South London. He qualified from Imperial College London in 2006, completing his basic surgical training in North West London. In 2009 he became a member of the Royal College of Surgeons of England.
He completed a Wellcome trust funded PhD in stem cell biology and tissue engineering at Imperial College in 2014. He was awarded an NIHR funded Academic Clinical Fellowship and Honorary Clinical Research Fellowship at Imperial College London. His research focuses on the evaluation of novel surgical technology and practice, and has co-authored over 60 peer-reviewed publications.
Dr Biba Stanton BMedSci (Hons) MBBS (Hons) MRCP PhD
Dr Biba Stanton is a specialist registrar in neurology at the Royal Free Hospital, with a clinical interest in behavioural neurology and functional disorders. She graduated in medicine from the University of Newcastle-Upon-Tyne in 2000 with distinction, having also been awarded first class honours in her intercalated Bachelor of Medical Science degree.
She was awarded a PhD in psychology from King’s College London in
Dr Ashutosh Wechalekar MD, FRCP, FRCPath, DM,
UK National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Campus, London, UK
Ashutosh Wechalekar is a Senior Lecturer and Honorary Consultant Haematologist at University College London Medical School and the Royal Free London NHS Foundation Trust.
He trained in haematology in the UK and Canada. In 2004, he joined the UK National Amyloidosis Centre funded by a grant from Leukaemia research fund and is a consultant at the centre since 2007. He is a board member of UK Myeloma
His clinical research has clarified the role of drugs like bortezomib in the treatment pathway for amyloidosis. His academic interests are focused on biomarkers in cardiac amyloidosis, novel imaging methods for the heart in all types of amyloidosis, characterization and treatment of systemic AL amyloidosis as well as multiple myeloma including clinical trials of new and novel agents in these disorders. He has published extensively in these areas.